Health-related outcomes and economic burden in Japan: focus on inflammatory bowel disease, multiple sclerosis, and depression
Healthcare Policy and Access, Takeda Pharmaceutical Company Limited, Chuou-ku, Tokyo, Japan
This series presents articles using data collected from the National Health and Wellness Survey1 in Japan to assess the burden of inflammatory bowel disease (IBD), multiple sclerosis (MS), and depression using a common methodology involving cases vs. controls and patient-reported outcome measures (PROMs).
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]